TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33188075
Drug: Sequential two-step
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential two-step cell-based assay measuring TNF-α production by CD14+16+ intermediate monocytes after EBV peptide stimulation
Study: 33188075
Drug: Sequential cell-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential cell-based assay examining monocyte and eBm5 cell response to EBV peptides
Study: 36389766
Drug: Anakinra (IL-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (IL-1 receptor antagonist)
Study: 35031013
Drug: Gestational diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestational diabetes mellitus (GDM) treatment
Study: 34310464
Drug: rAAV2/2‐ND4 gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV2/2‐ND4 gene therapy
Study: 36063821
Drug: Asundexian 10
Normalized name: Asundexian
DrugBank: Asundexian (DB19088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asundexian 10 mg
Study: 36063821
Drug: Asundexian 50
Normalized name: Asundexian
DrugBank: Asundexian (DB19088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asundexian 50 mg
Study: 39546314
Drug: Intensive Home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Home Treatment (IHT)
Study: 36461619
Drug: THRIVE (100%
Approvals — FDA: no, EMA: no, PMDA: no
Description: THRIVE (100% oxygen, 40 L/min)
Study: 36461619
Drug: Facemask (100%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facemask (100% oxygen, 6 L/min)
Study: 33068792
Drug: Androgen suppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen suppression for 6 months, starting either 4 months before or concurrently with definitive prostate radiation therapy
Study: 37743037
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination therapy
Study: 37792369
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin
Study: 33922507
Drug: DHA-rich tuna
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich tuna oil capsules (6 capsules per day) for 8 weeks
Study: 33922507
Drug: Placebo (Sunola
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Sunola oil) capsules (6 capsules per day) for 8 weeks
Study: 36440464
Drug: Omalizumab 300
Normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 300 mg
Study: 32037784
Drug: Concurrent exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent exercise with post-activation potentiation (CE-PAP)
Study: 32037784
Drug: Concurrent exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent exercise (CE)
Study: 39324726
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy
Study: 37174730
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control)
Study: 34582701
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy (asana and pranayama practice for 12 weeks)
Study: 34582701
Drug: Oral antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidiabetic drugs (OAD) alone
Study: 32887762
Drug: Combined scatter
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined scatter correction (CC)
Study: 35899371
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment control condition
Study: 33743869
Drug: IgM antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM antibodies
Study: 33743869
Drug: Neutralising antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralising antibodies over time
Study: 33743869
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies over time
Study: 35488213
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) and Motor Imagery (MI) in addition to Physical Therapy (PT)
Study: 33579288
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (long-acting beta-2 agonist [LABA] or long-acting muscarinic antagonist [LAMA]) in GOLD III/IV group
Study: 33579288
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy in GOLD III/IV group
Study: 33579288
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy in GOLD I/II group
Study: 38598572
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 12 months)
Study: 32041441
Drug: Microneedling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling with topical tacrolimus at 2 weeks intervals for a maximum of 6 months
Study: 32041441
Drug: Tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.1% ointment applied once daily for 6 months
Study: 32041441
Drug: Microneedling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling with topical tacrolimus
Study: 32692071
Drug: Treatment effect
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effect reporting
Study: 32107270
Drug: Daily sunscreen
Normalized name: ZINC OXIDE 220 mg in 1 mL TOPICAL CREAM [SPF 30 Daily Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sunscreen use (prevention)
Study: 32792358
Drug: Immune-checkpoint-blockade (ICB)
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune-checkpoint-blockade (ICB) treatment
Study: 35739094
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine (3 doses)
Study: 33518304
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of VE and n-3 fatty acids
Study: 32702891
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection (1 mL of 0.5% bupivacaine and 10 mg of triamcinolone acetonide)
Study: 32702891
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL of 0.5% bupivacaine and 1 mL of normal saline)
Study: 32717295
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg transdermal nicotine
Study: 34542418
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy using VR in the form of head-mounted displays (HMDs)
Study: 34542418
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy using a laptop computer supplemented by physical items (active control)
Study: 36111378
Drug: Dexmedetomidine 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.50 μg/kg
Study: 36111378
Drug: Nalbuphine 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.08 mg/kg
Study: 37962876
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy
Study: 33586453
Drug: Pre-ICH antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-ICH antiplatelet therapy
Study: 34233065
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors (GPI)
Study: 32172626
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment
Study: 33994515
Drug: Home-visit occupational
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home-visit occupational therapy using Management Tool for Daily Life Performance (MTDLP)
Study: 33994515
Drug: Home-visit occupational
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home-visit occupational therapy without using MTDLP (Control)
Study: 33028623
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by interval debulking surgery (arm B)
Study: 38052042
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG)
Study: 33549429
Drug: Virgin coconut
Normalized name: Jarrow Formulas Extra Virgin Coconut Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virgin coconut oil (VCO) 30 ml per day for four weeks
Study: 37403057
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (ST)
Study: 36305459
Drug: Peripheral venous
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral venous access in active treatment groups
Study: 34905446
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine (dose 1) and MMR on d 0 and EV71 vaccine (dose 2) and LA‐JEV on d 30 (Group 1)
Study: 34905446
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of doses 1 and 2 of EV71 vaccine on d 0 and 30, respectively (Group 3)
Study: 32960998
Drug: eDiary documentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: eDiary documentation of bowel movements and fecal incontinence episodes, prompted by twice-daily phone notifications, with adherence rates of 95% and notifications prompting 29.6% of entries.
Study: 32487163
Drug: multimodal hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: multimodal hand therapy
Study: 32487163
Drug: combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination therapy with both hand therapy and ultrasound therapy
Study: 34396816
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 100% lavender essential oil
Study: 35745231
Drug: Nutraceutical supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical supplements (omega‐3 fatty acids, anthocyanins, and alpha‐cyclodextrins) for 12 weeks
Study: 33631287
Drug: Soluble interleukin-6
Normalized name: interleukin-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble interleukin-6 receptor (sIL-6R)
Study: 32475634
Drug: Modern radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern radiotherapy delivery systems and treatment strategies
Study: 34806342
Drug: HCQ monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCQ monotherapy
Study: 33506858
Drug: Nudge (providing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nudge (providing a paper form for free vaccine delivery and contacts for occupational health services)
Study: 32799356
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics
Study: 34279976
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management
Study: 36251060
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FA, tNAA/tCr, NSE, motor score, and Epileptic Seizures (ES)
Study: 33993473
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (1.0 mg/kg/h after a loading dose of 0.3 mg/kg)
Study: 34318757
Drug: Standard-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CT
Study: 39481395
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg
Study: 36412328
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.25% plain bupivacaine
Study: 37160401
Drug: Anticholinergic drugs
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic drugs
Study: 34551104
Drug: Low-dose vaccine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vaccine
Study: 36207894
Drug: Medium-dose vaccine
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose vaccine
Study: 37584344
Drug: High-dose vaccine
Normalized name: Fluzone 2023-2024 high-dose vaccine Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vaccine
Study: 32994466
Drug: Belotecan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belotecan 0.5 mg/m2 for five consecutive days every 3 weeks
Study: 32994466
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m2 for five consecutive days every 3 weeks
Study: 34263581
Drug: Remimazolam 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam 0.2 mg/kg (R1 group)
Study: 34263581
Drug: Remimazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam 0.3 mg/kg (R2 group)
Study: 34263581
Drug: Remimazolam 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam 0.4 mg/kg (R3 group)
Study: 36630619
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy
Study: 32057103
Drug: Fluorescence cholangiography
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescence cholangiography using 0.05 mg/kg indocyanine green
Study: 33278671
Drug: Metformin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin group
Study: 34080572
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dapoxetine (Group 2)
Study: 35573309
Drug: 24 IU
Normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24 IU intranasal oxytocin
Study: 35908275
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 400 mg, 800 mg, or 1200 mg QD
Study: 38662318
Drug: Recombinant zoster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant zoster vaccine (RZV)
Study: 32744380
Drug: janagliflozin 25
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: janagliflozin 25 mg
Study: 32744380
Drug: janagliflozin 50
Normalized name: canagliflozin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: janagliflozin 50 mg
Study: 36130222
Drug: Whole almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole almonds (56 g/d)
Study: 35911237
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy with Acceptance and Commitment Therapy (CBT-ACT)
Study: 32702570
Drug: Durvalumab 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 10 mg/kg every 2 weeks
Study: 35076832
Drug: Parent–Child Interaction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent–Child Interaction Therapy (PCIT)
Study: 38042525
Drug: Osimertinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib monotherapy
Study: 36184253
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg/day)
Study: 33499521
Drug: Phototherapy kiosk
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phototherapy kiosk (PK) treatments for 10 weeks
Study: 36077723
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg/day
Study: 32639484
Drug: Untreated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated group (no treatment)
Study: 34476464
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST) for depression over 2 months
Study: 35398399
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST) for depression
Study: 37786451
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg/kg
Study: 37786451
Drug: Tocilizumab 4
Normalized name: tocilizumab 400 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 4 mg/kg
Study: 33199491
Drug: Genomically directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genomically directed therapy
Study: 34220720
Drug: Whey Protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey Protein (15 g)
Study: 34220720
Drug: Placebo (water,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (water, 100 ml)
Study: 35980261
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide (4-6 µg/kg)
Study: 35980261
Drug: Glycopyrronium bromide
Normalized name: Glycopyrronium bromide
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glycopyrronium bromide (4 µg/kg)
Study: 33410336
Drug: Brief Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Cognitive Behavioral Therapy for Insomnia (bCBTi) - four weekly sessions
Study: 32401718
Drug: Platelet rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet rich plasma intradermal injections
Study: 35003725
Drug: One-time combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-time combination cefazolin 2 g and metronidazole 500 mg preoperatively
Study: 35003725
Drug: Tinzaparin 4500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin 4500 units SC daily for at least 7 days after discharge
Study: 33157325
Drug: Open flap
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open flap debridement (OFD) + adjunctive photodynamic therapy (PDT)
Study: 39377226
Drug: RTS,S/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 vaccine
Study: 39566128
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment
Study: 35603652
Drug: Xinfeng Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng Capsule (XFC)
Study: 37522226
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg
Study: 39182330
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy
Study: 33862589
Drug: Flexyn2a vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexyn2a vaccine (10 µg)
Study: 35175316
Drug: Capecitabine maintenance
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1‐14 every 3 weeks) plus best supportive care (BSC)
Study: 37814832
Drug: Capecitabine maintenance
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine maintenance therapy
Study: 35763213
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral 600 IU vitamin D supplementation
Study: 33156757
Drug: Empirical TB
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical TB treatment
Study: 39122650
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg/day
Study: 36053934
Drug: Attention-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention-based cognitive behavioral treatment (nine weekly sessions)
Study: 39059373
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream
Study: 36413080
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg
Study: 32093742
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) monotherapy at a dosage of 0.05-0.1 mg/kg/day for 6 months
Study: 33765241
Drug: Outpatient Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient Acceptance and Commitment Therapy (O‐ACT)
Study: 32173882
Drug: Single-plane MFU-V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-plane MFU-V treatment (4.5 mm)
Study: 32173882
Drug: Dual-plane MFU-V
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-plane MFU-V treatment (4.5 and 3.0 mm)
Study: 33780315
Drug: Straight and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Straight and slow injection
Study: 33780315
Drug: Tunneled and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tunneled and fast injection
Study: 33780315
Drug: Tunneled and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tunneled and slow injection
Study: 35012439
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive stimulation (iCS) - 47 weekly sessions
Study: 35012439
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - maintained baseline treatments
Study: 37265385
Drug: rhTNK-tPA (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTNK-tPA (16 mg intravenous bolus)